目的:评价新辅助化疗在治疗进展期胃癌中的疗效及安全性。方法:采用Cochrane系统评价方法,检索Cochrane图书馆临床对照试验库,PubMed,Embase,Web of Knowledge,Elsevier,CBM数据库,CDDB及CNKI数据库,根据纳入和剔除标准选取文献,采用改良Jadad量表对纳入文献进行质量评价,应用Revman5.0软件对各评价指标进行Meta分析。结果:共纳入8项随机对照临床研究,研究对象1 531例。新辅助化疗组与单纯手术组在5年生存率、R0切除率方面比较,差异有统计学意义(P<0.05),其OR值分别为1.44(1.13-1.83,P=0.003)、1.44(1.11-1.88,P=0.006),而两组围手术期死亡率及术后并发症发生率比较,差异无统计学意义(P>0.05),其OR值分别为1.06(0.57-1.96,P=0.86)、1.20(0.90-1.61,P=0.22)。结论:新辅助化疗有利于提高进展期胃癌患者R0切除率,延长总生存期,且耐受性和安全性良好
References
[1]
Jemal A,Bray F,Center MM.Global cancer statistics[J].CA Cancer J Clin,2011,61(2):69-90.
[2]
Hartgrink HH,van de Velde CJ,Putter H,et al.Neo-adjuvant chemotherapy for operable gastric cancer:long term results of the Dutch randomised FAMTX trial[J].Eur J Surg Oncol,2004,30(6):643-649.
[3]
Schuhmacher C,Gretschel S,Lordick FJ,et al.Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia:European Organisation for Research and Treatment of Cancer randomized trial 40954[J].J Clin Oncol,2010,28(35):5 210-5 218.
[4]
Ge L,Wang HJ,Yin D,et al.Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer:a meta-analysis[J].World J Gastroenterol,2012,18(48):7 384-7 393.
[5]
Yoshikawa T,Sasako M,Yamamoto S,et al.PhaseⅡstudy of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer[J].Br J Surg,2009,96(9):1 015-1 022.
Kelsen D,Karpeh M,Schwartz G,et al.Neoadjuvant therapy of high-risk gastric cancer:aphaseⅡtrial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil[J].J Clin Oncol,1996,14(6):1 818-1 828.
[8]
Jadad AR,Moore RA,Carroll D,et al.Assessing the quality of reports of randomized clinical trials:is blinding necessary?[J].Control Clin Trials,1996,17(1):1-12.
[9]
Kobayashi T,Kimura T.Long-term outcome of preoperative chemotherapy with 5’-deoxy-5-fluorouridine(5’-DFUR)for gastric cancer[J].Gan to Kagaku Ryoho,2000,27(10):1 521-1 526.
[10]
Nio Y,Koike M,Omori H,et al.A randomized consent design trial of neoadjuvant chemotherapy with tegafur plus uracil(UFT)for gastric cancer-a single institute study[J].Anticancer Res,2004,24(3b):1 879-1 887.
Alberts SR,Cervantes A,van de Velde CJ.Gastric cancer:epidemiology,pathology and treatment[J].Ann Oncol,2003,14:ii31-ii36.
[13]
Nashimoto A,Nakajima T,Furukawa H,et al.Randomized trial of adjuvant chemotherapy with mitomycin,fluorouracil,and cytosine arabinoside followed by oral fluorouracil in serosa-negative gastric cancer:Japan Clinical Oncology Group 9206-1[J].J Clin Oncol,2003,21(12):2 282-2 287.
[14]
Jemal A,Siegel R,Xu J,et al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5):277-300.
[15]
Cunningham D,Allum WH,Stenning SP,et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J].N Engl J Med,2006,355(1):11-20.
[16]
Wang XL,Wu GX,Zhang MD,et al.A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer[J].Oncol Rep,2000,7(2):241-244.
[17]
Boige V,Pignon J,Saint-Aubert B,et al.Final results of a randomized trial comparing preoperative 5-fluorouracil(F)/cisplatin(P)to surgery alone in adenocareinoma of stomach and lower esophagus(ASL):FNLCCACCORD07-FFCD 9703 trial[J].J Clin Oncol,2007,25(18):4 510.
